INDICATION STATEMENT

RITUXAN^® (Rituximab) is indicated for the treatment of patients with:

• Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy
• Non-progressing (including stable disease), low‑grade, CD20‑positive, B‑cell NHL, as a single agent, after first‑line CVP chemotherapy
• Relapsed or refractory, low‑grade or follicular, CD20‑positive, B‑cell NHL as a single agent
  • Weekly x4
  • Weekly x8
  • Bulky disease
  • Retreatment
• Previously untreated diffuse large B‑cell, CD20‑positive NHL in combination with CHOP or other anthracycline‑based chemotherapy regimens

People with serious infections should not receive RITUXAN.

IMPORTANT SAFETY INFORMATION

• RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
• RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
• The most common side effects of RITUXAN seen in patients with non-Hodgkin’s lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
• Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor

Please see full Prescribing Information, including Medication Guide.

INDICATION STATEMENT

RITUXAN^® (Rituximab) is indicated for the treatment of patients with:

• Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC)

People with serious infections should not receive RITUXAN.

IMPORTANT SAFETY INFORMATION

• RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
• RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
• The most common side effects of RITUXAN seen in clinical trials of patients with CLL were infusion reactions and low white blood cells, which can increase the risk of infections. Before starting treatment with RITUXAN it is important for you to talk to your doctor about your medical history.
• Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including Medication Guide.

INDICATION STATEMENT

RITUXAN^® (Rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

IMPORTANT SIDE EFFECT INFORMATION

Rituxan therapy can result in serious side effects, some which can be life-threatening. These include:

• infusion reactions
• tumor lysis syndrome (TLS)
• severe mucocutaneous reactions
• progressive multifocal leukoencephalopathy (PML)

Other serious, potentially life threatening side effects are:

• hepatitis B infection that may become active again
• serious infections
• heart problems
• low blood cell counts

Common side effects include infections and infusion reactions.

Before treatment with Rituxan, patients should tell their doctor if they have an infection, including one that will not go away or keeps coming back.

If patients experience any symptoms or side effects during or after Rituxan treatment, they should seek immediate medical attention.

These are not all of the possible side effects with Rituxan. Tell your doctor about any side effect that bothers you or that does not go away.

Please read the Rituxan Full Prescribing Information including the Medication Guide.

If you have any questions about this information, be sure to discuss them with your doctor.

INDICATION STATEMENT

Rituxan^® (rituximab) is used with glucocorticoids to treat adults with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA).

People with serious infections should not receive RITUXAN.

IMPORTANT SIDE EFFECT INFORMATION

Rituxan therapy can result in serious side effects, some which can be life-threatening. These include:

• infusion reactions
• tumor lysis syndrome (TLS)
• severe mucocutaneous reactions
• progressive multifocal leukoencephalopathy (PML)

Other serious, potentially life threatening side effects are:

• hepatitis B infection that may become active again
• serious infections
• heart problems
• low blood cell counts

Common side effects in the WG and MPA study included infections, nausea, diarrhea, headache, muscle spasms, anemia, peripheral edema (swollen hands and feet)

Before treatment with Rituxan, patients should tell their doctor if they have an infection, including one that will not go away or keeps coming back.

If patients experience any symptoms or side effects during or after Rituxan treatment, they should seek immediate medical attention.

These are not all of the possible side effects with Rituxan. Tell your doctor about any side effect that bothers you or that does not go away.

If you have any questions about this information, be sure to discuss them with your doctor.

Please read the Rituxan Full Prescribing Information including the Medication Guide.